Analysts Project 120% Upside To Dyne Therapeutics, Inc. (DYN)

Group 1 - Dyne Therapeutics, Inc. (NASDAQ:DYN) has seen returns of over 23% in the last three months and is rated as a Strong Buy by Wall Street analysts, with a projected upside of 120% as of January 12 [1] - Evercore ISI's Gavin Clark-Gartner recently adjusted the price target for DYN to $36 from $38 while maintaining an Outperform rating, indicating over 100% upside potential from the recent closing price [2] - Oppenheimer upgraded DYN's rating to Outperform and raised its price target to $40 from $11, citing the anticipated Phase 3 trial readout for a competitor's RNA therapy as a significant factor [3] Group 2 - A key catalyst for DYN's potential growth is the success of its therapeutic zeleciment basivarsen for treating myotonic dystrophy type 1 (DM1), along with the possibility of FDA review for its candidate for Duchenne muscular dystrophy (DMD) [4] - Dyne Therapeutics focuses on developing treatments for genetically driven neuromuscular diseases, positioning itself in a niche healthcare market [5]